Loading company…
Tubulis GmbH develops antibody-drug conjugates for targeted cancer therapies, with its lead candidate TUB-030 in a Phase I/IIa trial.
Founded in 2016 and based in Munich, Germany, Tubulis GmbH develops antibody-drug conjugates for targeted cancer therapies. In October 2025, it raised EUR 344 million in Series C funding co-led by Venrock Healthcare Capital Partners, Wellington Management and Ascenta Capital. The round valued the company at EUR 466.586 mn post-money, and its lead product TUB-030 is in a Phase I/IIa trial for advanced solid tumors. Revenue comes mainly from partnerships and licensing agreements with pharmaceutical companies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in